as a combination of two analytical tools, to produce a budget optimising management system.

**Material and methods** Dispersing data for the first 6 months of 2019 from the haematology, oncology and chemotherapy departments were collected. ABC analysis was performed: class A accounted for 72% of total expenditure, class B for 23% and class C for 5%. The VEN tool was further extended to a score index (summarising the characteristics of the health impact of the medicines) grouped into three classes: class V for vital, class E for essential and class N for non-essential medicines. Crosstab ABC-VEN analysis resulted in three major categories: I (AV, BV, CV, AE), II (BE, CE) and III (AN, BN, CN).

**Result** Fifty-seven CA-MtADR were analysed. Expenditure for CA-MtADR was 40% of the total expenditure for medicines in the hospital. According to the ABC analysis, 7 medicines (12%) were class A, 12 medicines (21%) class B, and 38 (67%) class C. According to the VEN analysis, 9 medicines (16%) were characterised as V, 43 (75%) as E and 5 (9%) as N. According to the ABC-VEN crosstab analysis, category I (eg. daratumumab (ATC L01XC24)) included 16 medicines (28%), category II (eg. trastuzumab emtansine (ATC L01XC14)) 36 medicines (63%) and category III (eg. pantoprazole (ATC A02BC02)) 5 medicines (9%).

**Conclusion and relevance** ABC-VEN crosstab analysis revealed three categories of corresponding priority: CA-MtADR category I, including expensive and/or vital medicines which need patient oriented personalised stock management; CA-MtADR category II, medicines which should be monitored with special consideration to ensure availability (because they are essential); and CA-MtADR category III, medicines where stock is according to demand (due to low price). ABC, VEN and ABC-VEN analysis can assist in developing a robust approach to improve budgetary planning in hospitals.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**1ISG-006 EFFECTIVENESS EVALUATION OF HIGH COST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION**

A Isoardo*, E Grande, MM Ferrero, C Fruttero. A0 S Croce E Carle, SC Farmacia Ospedaliera, Cuneo, Italy

10.1136/ejhpharm-2020-eahpconf.6

**Background and importance** Lung cancer has a poor prognosis and is the most common cause of cancer death. In Italy, lung cancer is the third most common cancer. Treatment decisions are based on the histology and molecular characteristics of the tumour. Treatment options for non-small-cell lung cancer (NSCLC) are targeted therapies (tyrosine kinase inhibitors (TKIs)), immunotherapy or chemotherapy.

**Aim and objectives** To analyse drug effectiveness for advanced NSCLC in our hospital, to assess compliance with clinical practice guidelines and to perform an economic evaluation.

**Material and methods** We identified all patients with advanced NSCLC treated with high cost drugs (pemetrexed, erlotinib, gefitinib, afatinib, osimertinib, crizotinib, pembrolizumab and nivolumab) from 1 May 2016 to 30 April 2018. Patients were stratified by age, gender, therapy, ECOG (Eastern Cooperative Oncology Group) performance status (PS) and type of cancer treatment (targeted therapy, immunotherapy or the historical standard of care, pemetrexed). We assessed progression free survival (PFS) and overall survival (OS) with the Kaplan–Meier method. We assessed compliance with Italian clinical practice guidelines and we analysed drug costs.

**Results** We found 92 cases of NSCLC: 70% were men and mean age was 65 years. We found that 50% were treated with pemetrexed, 30% with immunotherapy and 20% with targeted therapy; 61% were first-line treatments. Median PFS was 4.4 months and median OS was 8.6 months. Targeted therapy was most likely to improve PFS (5.9 months), followed by pemetrexed (4.3 months) and immunotherapy (2.9 months). Targeted therapy was similarly best for OS outcome (15.3 months), followed by immunotherapy (11 months) and pemetrexed (8.6 months). After patient stratification, there was no statistically significant difference between age, gender or therapy groups. PS was an indicator of better prognosis: cases with a baseline PS score of 0 (75%) were associated with longer PFS (5.5 months) and OS (11 months). Compliance with clinical practice guidelines was high. Afatinib and gefitinib were the least expensive TKIs. Nivolumab was less expensive than pembrolizumab.

**Conclusion and relevance** TKIs for the management of NSCLC are cost effective. Afatinib is an important first-line option for EGFR mutation positive NSCLC. Gefitinib can be an effective second-line therapy. Pemetrexed can still be recommended for EGFR and ALK wild-type non-squamous advanced NSCLC. However, our analysis suggests a limited effectiveness of immunotherapy.

**REFERENCES AND/OR ACKNOWLEDGEMENTS**

No conflict of interest.

**1ISG-007 NEW CANCER DRUG APPROVALS IN PORTUGAL**

A Alcobia*, A Soares. Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal

10.1136/ejhpharm-2020-eahpconf.7

**Background and importance** In Portugal, all new drugs, after EMA approval, undergo a national health technology assessment process to decide their reimbursement status, by the SNS (Portuguese National Health System).

**Aim and objectives** The objective of this study was characterisation of the drug approval processes for cancer drugs by the INFARMED (Portuguese Regulatory Agency).

**Material and methods** The 10 latest drugs approved for different types of cancer were analysed, considering their therapeutic indication, type of economic analysis performed and efficacy outcome.

**Results** This analysis was performed in October 2019. The 10 latest cancer drugs approved (midostaurin, olaparib, brentuximab vedotin, pomalidomide, durvalumab, venetoclax, ixazomib, alecetinib, atezolizumab and cabozantinib) are for use in refractory disease (60%), first-line treatment of metastatic disease (20%) and maintenance therapy in patients who have not progressed after first-line therapy (20%). A cost utility analysis was made for seven drugs, cost efficacy for two drugs and a cost minimisation analysis for two drugs (one of the drugs had two types of analysis as there were two different groups of patients). The efficacy outcome considered was overall survival in 60% and progression free survival in 30%. One evaluation considered overall response. The average HR for the